Bluejay Diagnostics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.95) per share. This is a 85.53 percent increase over losses of $(13.48) per share from the same period last year.
ACTON, Mass., May 07, 2026 -- Bluejay Diagnostics, Inc. , a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update...
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today
The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including reactivity, for use in Symphony™ cartridge manufacturing intended for clinical and potential future
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2024-03-28 | -1360.00 | -2848.00 | -109.41% |
| 2023-11-09 | -1344.00 | -3328.00 | -147.62% |
| 2023-08-14 | -2240.00 | -4400.00 | -96.43% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BJDX | +11.46% | +9.74% | -19.79% | -66.35% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +8.49% | +14.38% | -16.35% | -79.04% |